NCT03579940View on ClinicalTrials.gov

A Study of Lasmiditan in Healthy Japanese and Caucasian Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

August 9, 2018

Study Completion Date

August 9, 2018

Conditions
Healthy
Interventions
DRUG

Lasmiditan

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

75247

Covance, Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03579940 - A Study of Lasmiditan in Healthy Japanese and Caucasian Participants | Biotech Hunter | Biotech Hunter